bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-30-2720

Order Name:
PIVKA II

 
Useful For:
Determination of PIVKA-II in human serum.
               
Use as an aid for diagnosis of HCC (hepato-cellular carcinoma), monitoring of high risk patients (Hepatitis C virus infections, hepatitis/cirrhosis, hepatitis B virus infections) for development of HCC, and in management of HCC.
 
Methodology:
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
AliasesName:
Antagonist-II
Des-gamma carboxyprothrombin
Protein Induced Vitamin K Absence 
 
 
 
Test Code:
090-30-2720

Order Name:
PIVKA II

 
Collection Specimen Or Container:
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 1 mL
 
Sub Mission Container:
Plastic vial
 
Rejection Criteria:
Hemolysis: 4+ reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum (keep in original tube) Room temperature, 20oC to 28oC 8 hours
Serum Refrigerated, 2oC to 8oC 7 days
Frozen, -20oC 1 year
 
 
 
Test Code:
090-30-2720

Order Name:
PIVKA II

 
Method detail:
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
Schedule:
Tested Daily (24 Hours)
 
Turnaround Time:
Specimen collected to reported within 2:00 Hours (120 Mins)
 
Performing Location:
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time:
5 days
 
 
 
Test Code:
090-30-2720

Order Name:
PIVKA II

 
 
Clinical Information:
PIVKA-II is abnormal des-carboxylated prothrombin (DCP) present in vitamin K deficiency or in patients treated with warfarin or phenprocoumon. The des-carboxylated prothrombins are functionally defective because the cannot bind calcium and phospholipid. Measuring PIVKA-II permits the detection of biochemical Vitamin K deficiency before the results of conventional coagulation tests are changed or hemorrhage occurs. PIVKA-II is absent in normal individuas, but in liver disease and liver malignancy PIVKA-II can present even without Vitamin K deficiency.                                                                    

PIVKA-II levels are determined to aid in the diagnosis and prognosis of patients with HCC and in monitoring HCC patients under therapy.
 
Reference Value:
Japan: 11.12 - 32.01 mAU/mL    
Europe: 17.36 - 50.90 mAU/mL
 
Clinical Reference:
Manufacturer’s Reagent package insert Architect PIVKA-II, June 2015, ABBOTT GmbH & Co.KG, Max-Planck-Ring2, 65205 Wiesbaden, Germany.